Sai Life Sciences Q3 PAT up about 86% YoY, revenue grows about 27%
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.8 pts more than Nifty Smallcap 250 and 5.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sai Life Sciences posted Q3 FY26 consolidated revenue of Rs 5,564.64 million, up 26.5% YoY, with PAT at Rs 1,003.75 million, up 86% YoY. For 9M FY26, consolidated revenue rose 42.6% to Rs 15,903.53 million and PAT nearly tripled to Rs 2,446.74 million. Standalone 9M revenue grew 45% and PAT rose 186%. An exceptional loss of Rs 82.93 million was booked for the new Labour Codes wage impact. Deloitte issued an unmodified review.
Strong top-line and earnings growth with margin expansion; one-time Labour Code charge is a minor drag. Overall positive.